Childhood Vascular Tumors Treatment (PDQ®)–Patient Version
General Information About Childhood Vascular Tumors
- Childhood vascular tumors form from cells that make blood vessels or lymph vessels.
- Tests are used to detect (find) and diagnose childhood vascular tumors.
- Childhood vascular tumors may be classified into four groups.
- Benign tumors
- Intermediate (locally aggressive) tumors
- Intermediate (rarely metastasizing) tumors
- Malignant tumors
Childhood vascular tumors form from cells that make blood vessels or lymph vessels.
Vascular tumors can form from abnormal blood vessel or lymph vessel cells anywhere in the body. They may be benign (not cancer) or malignant (cancer). There are many types of vascular tumors. The most common type of childhood vascular tumor is infantile hemangioma, which is a benign tumor that usually goes away on its own.
Because malignant vascular tumors are rare in children, there is not a lot of information about what treatment works best.
Tests are used to detect (find) and diagnose childhood vascular tumors.
The following tests and procedures may be used:
- Physical exam and history: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps, lesions, or anything else that seems unusual. A history of the patient’s health habits and past illnesses and treatments will also be taken.
- Ultrasound exam: A procedure in which high-energy sound waves (ultrasound) are bounced off internal tissues or organs and make echoes. The echoes form a picture of body tissues called a sonogram. The picture can be printed to be looked at later.
- CT scan (CAT scan): A procedure that makes a series of detailed pictures of areas inside the body, taken from different angles. The pictures are made by a computer linked to an x-ray machine. A dye may be injected into a vein or swallowed to help the organs or tissues show up more clearly. This procedure is also called computed tomography, computerized tomography, or computerized axial tomography.
- MRI (magnetic resonance imaging): A procedure that uses a magnet, radio waves, and a computer to make a series of detailed pictures of areas inside the body. This procedure is also called nuclear magnetic resonance imaging (NMRI).
- Biopsy: The removal of cells or tissues so they can be viewed under a microscope by a pathologist to check for signs of cancer. A biopsy is not always needed to diagnose a vascular tumor.
Childhood vascular tumors may be classified into four groups.
Benign tumors are not cancer. This summary has information about the following benign vascular tumors:
Intermediate (locally aggressive) tumors
Intermediate tumors that are locally aggressive often spread to the area around the tumor. This summary has information about the following locally aggressive vascular tumors:
Intermediate (rarely metastasizing) tumors
Intermediate (rarely metastasizing) tumors sometimes spread to other parts of the body. This summary has information about the following vascular tumors that rarely metastasize:
Malignant tumors are cancer. This summary has information about the following malignant vascular tumors:
Treatment Option Overview
- There are different types of treatment for childhood vascular tumors.
- Children with childhood vascular tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.
- Treatment for childhood vascular tumors may cause side effects.
- Eleven types of standard treatment are used:
- Beta-blocker therapy
- Radiation therapy
- Targeted therapy
- Other drug therapy
- New types of treatment are being tested in clinical trials.
- Patients may want to think about taking part in a clinical trial.
- Patients can enter clinical trials before, during, or after starting their cancer treatment.
- Follow-up tests may be needed.
There are different types of treatment for childhood vascular tumors.
Different types of treatment are available for children with vascular tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.
Because vascular tumors in children are rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.
Children with childhood vascular tumors should have their treatment planned by a team of health care providers who are experts in treating cancer in children.
Treatment will be overseen by a pediatric oncologist, a doctor who specializes in treating children with cancer. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with cancer and who specialize in certain areas of medicine. These may include the following specialists:
Treatment for childhood vascular tumors may cause side effects.
Some treatments, such as chemotherapy and radiation therapy, cause side effects that continue or appear months or years after treatment has ended. These are called late effects. Late effects of treatment may include the following:
- Physical problems.
- Changes in mood, feelings, thinking, learning, or memory.
- Second cancers (new types of cancer).
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. (See the PDQ summary on Late Effects of Treatment for Childhood Cancer for more information).
Eleven types of standard treatment are used:
Beta-blockers are drugs that decrease blood pressure and heart rate. When used in patients with vascular tumors, beta-blockers may help shrink the tumors. Beta-blocker therapy may be given by vein (IV), by mouth, or placed on the skin (topical). The way the beta-blocker therapy is given depends on the type of vascular tumors and where the tumor first formed.
The beta-blocker propranolol is usually the first treatment for hemangiomas. Infants treated with IV propranolol may need to have their treatment started in a hospital. Propranolol is also used to treat benign vascular tumor of liver and kaposiform hemangioendothelioma.
Other beta-blockers used to treat vascular tumors include atenolol, nadolol, and timolol.
See the drug information summary on Propranolol Hydrochloride for more information.
The following types of surgery may be used to remove many types of vascular tumors:
- Excision: Surgery to remove the entire tumor and some of the healthy tissue around it.
- Laser surgery: A surgical procedure that uses a laser beam (a narrow beam of intense light) as a knife to make bloodless cuts in tissue or to remove a skin lesion such as a tumor. Surgery with a pulsed dye laser may be used for some hemangiomas. This type of laser uses a beam of light that targets blood vessels in the skin. The light is changed into heat and the blood vessels are destroyed without damaging nearby skin.
- Curettage: A procedure in which abnormal tissue is removed using a small, spoon-shaped instrument called a curette.
- Total hepatectomy and liver transplant: A surgical procedure to remove the entire liver followed by a transplant of a healthy liver from a donor.
The type of surgery used depends on the type of vascular tumor and where the tumor formed in the body.
For malignant tumors, after the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Embolization is a procedure that uses particles, such as tiny gelatin sponges or beads, to block blood vessels in the liver. It may be used to treat some benign vascular tumors of the liver and kaposiform hemangioendothelioma.
Chemotherapy is a treatment that uses drugs to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. There are different ways to give chemotherapy:
- Systemic chemotherapy: When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach tumor cells throughout the body. Sometimes more than one anticancer drug is given. This is called combination chemotherapy.
- Topical chemotherapy: When chemotherapy is applied to the skin in a cream or lotion, the drugs mainly affect tumor cells in the treated area.
- Regional chemotherapy: When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect tumor cells in those areas.
The way the chemotherapy is given depends on the type of the vascular tumor being treated. Systemic and topical chemotherapy are used to treat some vascular tumors.
Sclerotherapy is a treatment used to destroy the blood vessel that leads to the tumor and the tumor. A liquid is injected into the blood vessel, causing it to scar and break down. Over time, the destroyed blood vessel is absorbed into normal tissue. The blood flows through nearby healthy veins instead. Sclerotherapy is used in the treatment of epithelioid hemangioma.
The way the radiation therapy is given depends on the type of the vascular tumor being treated. External radiation is used to treat some vascular tumors.
Targeted therapy is a type of treatment that uses drugs or other substances to attack specific tumor cells. Targeted therapies usually cause less harm to normal cells than chemotherapy or radiation therapy do. Different types of targeted therapy are being used or studied to treat childhood vascular tumors:
- Angiogenesis inhibitors: Angiogenesis inhibitors are drugs that stop cells from dividing and prevent the growth of new blood vessels that tumors need to grow. The targeted therapy drugs thalidomide, sorafenib, pazopanib, and sirolimus are angiogenesis inhibitors used to treat childhood vascular tumors.
- Mammalian target of rapamycin (mTOR) inhibitors: mTOR inhibitors block a protein called mTOR, which may keep cancer cells from growing and prevent the growth of new blood vessels that tumors need to grow.
- Kinase inhibitors: Kinase inhibitors block signals needed for tumors to grow. Trametinib is being studied to treat epithelioid hemangioendothelioma.
Immunotherapy is a treatment that uses the patient’s immune system to fight disease. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against disease.
The following types of immunotherapy are being used in the treatment of childhood vascular tumors:
- Interferon is a type of immunotherapy used to treat childhood vascular tumors. It interferes with the division of tumor cells and can slow tumor growth. It is used in the treatment of juvenile nasopharyngeal angiofibroma, kaposiform hemangioendothelioma, and epithelioid hemangioendothelioma.
- Immune checkpoint inhibitor therapy: Some types of immune cells, such as T cells, and some cancer cells have certain proteins, called checkpoint proteins, on their surface that keep immune responses in check. When cancer cells have large amounts of these proteins, they will not be attacked and killed by T cells. Immune checkpoint inhibitors block these proteins and the ability of T cells to kill cancer cells is increased.
There are two types of immune checkpoint inhibitor therapy:
- CTLA-4 inhibitor: CTLA-4 is a protein on the surface of T cells that helps keep the body’s immune responses in check. When CTLA-4 attaches to another protein called B7 on a cancer cell, it stops the T cell from killing the cancer cell. CTLA-4 inhibitors attach to CTLA-4 and allow the T cells to kill cancer cells. Ipilimumab is a type of CTLA-4 inhibitor being studied in the treatment of angiosarcoma of the soft tissue.
- PD-1 inhibitor: PD-1 is a protein on the surface of T cells that helps keep the body’s immune responses in check. When PD-1 attaches to another protein called PDL-1 on a cancer cell, it stops the T cell from killing the cancer cell. PD-1 inhibitors attach to PDL-1 and allow the T cells to kill cancer cells. Nivolumab is a type of PD-1 inhibitor being studied in the treatment of angiosarcoma of the soft tissue.
Other drug therapy
Other drugs used to treat childhood vascular tumors or manage their effects include the following:
- Steroid therapy: Steroids are hormones made naturally in the body. They can also be made in a laboratory and used as drugs. Steroid drugs help shrink some vascular tumors. Corticosteroids, such as prednisone and methylprednisolone, are used to treat infantile hemangioma.
- Non-steroidal anti-inflammatory drugs (NSAIDs): NSAIDs are commonly used to decrease fever, swelling, pain, and redness. Examples of NSAIDs are aspirin, ibuprofen, and naproxen. In the treatment of vascular tumors, NSAIDs can increase the flow of blood through the tumors and decrease the chance that an unwanted blood clot will form.
- Antifibrinolytic therapy: These drugs help the blood clot in patients who have Kasabach-Merritt syndrome. Fibrin is the main protein in a blood clot that helps stop bleeding and heal wounds. Some vascular tumors cause fibrin to break down and the patient's blood does not clot normally, causing uncontrolled bleeding. Antifibrinolytics help prevent the breakdown of fibrin.
New types of treatment are being tested in clinical trials.
Information about clinical trials is available from the NCI website.
Patients may want to think about taking part in a clinical trial.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the research process. Clinical trials are done to find out if new treatments are safe and effective or better than the standard treatment.
Many of today's standard treatments are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way disease will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose tumors have not gotten better. There are also clinical trials that test new ways to stop tumors from recurring (coming back) or reduce the side effects of treatment.
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Follow-up tests may be needed.
Some of the tests that were done to diagnose the vascular tumor may be repeated. Some tests will be repeated in order to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the tumor has recurred (come back). These tests are sometimes called follow-up tests or check-ups.
For information about the treatments listed below, see the Treatment Option Overview section.
Infantile hemangiomas are the most common type of benign vascular tumor in children. Infantile hemangiomas form when immature cells that are meant to form blood vessels form a tumor instead. An infantile hemangioma may also be called a "strawberry mark."
These tumors are not usually seen at birth but appear when the infant is 3 to 6 weeks old. Most hemangiomas get bigger for about 5 months and then stop growing. The hemangiomas slowly fade away over the next several years, but a red mark or loose or wrinkled skin may remain. It is rare for an infantile hemangioma to come back.
Infantile hemangiomas may be on the skin, in the tissue below the skin, and/or in an organ. They are usually on the head and neck but can be anywhere on or in the body. Hemangiomas may appear as a single lesion, one or more lesions spread over a larger area of the body, or multiple lesions in more than one part of the body. Lesions that are spread over a larger area of the body or multiple lesions are more likely to cause problems.
Infantile hemangioma with minimal or arrested growth (IH-MAG) is a certain type of infantile hemangioma that is seen at birth and does not tend to get bigger. The lesion appears as light and dark areas of redness in the skin. The lesions are usually on the lower body but can be on the head and neck. Hemangiomas of this type go away over time without treatment.
Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get the disease; not having risk factors doesn’t mean that you will not get the disease. Talk with your child's doctor if you think your child may be at risk.
Infantile hemangiomas are more common in the following:
Other risk factors for infantile hemangiomas include the following:
- Having a family history of infantile hemangioma, usually in a mother, father, sister, or brother.
- Having certain syndromes.
- PHACE syndrome: A syndrome in which the hemangioma spreads across a large area of the body (usually the head or face). Other health problems that affect the large blood vessels, heart, eyes, and/or brain may also occur.
- LUMBAR/PELVIS/SACRAL syndrome: A syndrome in which the hemangioma spreads across a large area of the lower back. Other health problems that affect the urinary system, genitals, rectum, anus, brain, spinal cord, and nerve function may also occur.
Having more than one hemangioma or an airway or ophthalmic hemangioma increases the risk of having other health problems.
- Multiple hemangiomas: Having more than five hemangiomas on the skin is a sign that there may be hemangiomas in an organ. The liver is affected most often. Heart, muscle, and thyroid gland problems can also occur.
- Airway hemangiomas: Hemangiomas in the airway usually occur along with a large, beard-shaped area of hemangioma on the face (from the ears, around the mouth, lower chin, and front of neck). It is important that airway hemangiomas are treated before the child has trouble breathing.
- Ophthalmic hemangiomas: Hemangiomas that involve the eye may cause vision problems or blindness. Infantile hemangiomas can occur in the conjunctiva (a membrane that lines the inner surface of the eyelid and covers the front part of the eye). These hemangiomas may be linked with other abnormal conditions of the eye. It is important that children with an ophthalmic hemangioma are examined by an ophthalmologist.
Signs and Symptoms
Infantile hemangiomas may cause any of the following signs and symptoms. Check with your child’s doctor if your child has any of the following:
- Skin lesions: An area of spidery veins or lightened or discolored skin may appear before the hemangioma does. Hemangiomas occur as firm, warm, bright red to crimson lesions on the skin or may look like a bruise. Lesions that form ulcers are also painful. Later, as the hemangiomas go away, they begin fading in the center before flattening and losing color.
- Lesions below the skin: Lesions that grow under the skin in the fat may appear blue or purple. If the lesions are deep enough under the skin surface, they may not be seen.
- Lesions in an organ: There may be no signs that hemangiomas have formed on an organ.
Although most infantile hemangiomas are nothing to worry about, if your child develops any lumps or red or blue marks on the skin check with your child's doctor. He or she can refer the child to a specialist if needed.
A physical exam and history are usually all that are needed to diagnose infantile hemangiomas. If there is something about the tumor that looks unusual, a biopsy may be done. If the hemangioma is deeper inside the body with no change to the skin, or the lesions are spread across a large area of the body, an ultrasound may be done. See the General Information section for a description of these tests and procedures.
Most hemangiomas fade and shrink without treatment. If the hemangioma is large or causing other health problems, treatment may include the following:
- Propranolol or other beta-blocker therapy.
- Steroid therapy, before beta-blocker therapy is begun or when beta-blockers cannot be used.
- Pulsed dye laser surgery, for hemangiomas that have ulcers or have not completely gone away.
- Surgery (excision) for hemangiomas that have ulcers, cause vision problems, or have not completely gone away. Surgery may also be used for lesions on the face that do not respond to other treatment.
- Topical beta-blocker therapy for hemangiomas that are in one area of the skin.
- Combined therapy, such as propranolol and steroid therapy or propranolol and topical beta-blocker therapy.
- A clinical trial of beta-blocker therapy (nadolol and propranolol).
- A clinical trial of topical beta-blocker therapy (timolol).
Congenital hemangioma is a benign vascular tumor that begins forming before birth and is fully formed when the baby is born. They're usually on the skin but can be in another organ. A congenital hemangioma may occur as a rash of purple spots and the skin around the spot may be lighter.
There are three types of congenital hemangiomas:
- Rapidly involuting congenital hemangioma: These tumors go away on their own 12 to 15 months after birth. They can form ulcers, bleed, and cause temporary heart and blood clotting problems. The skin may look a little different even after the hemangiomas go away.
- Partial involuting congenital hemangioma: These tumors do not go away completely.
- Non-involuting congenital hemangioma: These tumors never go away on their own.
Treatment of rapidly involuting congenital hemangioma and partial involuting congenital hemangioma may include the following:
- Observation only.
Treatment of non-involuting congenital hemangioma may include the following:
Benign Vascular Tumors of the Liver
Benign vascular tumors of the liver may be focal vascular lesions (a single lesion in one area of the liver), multiple liver lesions (multiple lesions in one area of the liver), or diffuse liver lesions (multiple lesions in more than one area of the liver).
The liver has many functions, including filtering blood and making proteins needed for blood clotting. Sometimes, blood that normally flows through the liver is blocked or slowed by the tumor. This sends blood directly to the heart without going through the liver and is called a liver shunt. This can cause heart failure and problems with blood clotting.
Focal Vascular Lesions
Focal vascular lesions are usually rapidly involuting congenital hemangiomas or non-involuting congenital hemangiomas.
Treatment of focal vascular lesions of the liver depends on whether symptoms occur and may include the following:
Multiple and Diffuse Liver Lesions
Multifocal and diffuse lesions of the liver are usually infantile hemangiomas. Diffuse lesions of the liver can cause serious effects, including problems with the thyroid gland and heart. The liver can enlarge, press on other organs, and cause more symptoms.
See the General Information section for a description of tests and procedures used to diagnose multifocal or diffuse benign vascular lesions.
Treatment of multifocal liver lesions may include the following:
Treatment of diffuse liver lesions may include the following:
Spindle Cell Hemangioma
Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get the disease; not having risk factors doesn’t mean that you will not get the disease. Talk with your child's doctor if you think your child may be at risk. Spindle cell hemangiomas are likely to occur in children with the following syndromes:
Spindle cell hemangiomas appear on or under the skin. They are painful red-brown or bluish lesions that usually appear on the arms or legs. They can begin as one lesion and develop into more lesions over years.
There is no standard treatment for spindle cell hemangiomas. Treatment may include the following:
Spindle cell hemangiomas may come back after surgery.
Epithelioid hemangiomas usually form on or in the skin, especially the head, but can occur in other areas, such as bone.
Signs and Symptoms
Epithelioid hemangiomas are sometimes caused by injury. On the skin, they may appear as firm pink to red bumps and may be itchy. Epithelioid hemangioma of the bone may cause swelling, pain, and weakened bone in the affected area.
There is no standard treatment for epithelioid hemangiomas. Treatment may include the following:
Epithelioid hemangiomas often come back after treatment.
Pyogenic granuloma is also called lobular capillary hemangioma. It is most common in older children and young adults but may occur at any age.
The lesions are sometimes caused by injury or from the use of certain medicines, including birth control pills and retinoids. They may also form for no known reason inside capillaries (the smallest blood vessels), arteries, veins, or other places on the body. Usually there is only one lesion, but sometimes multiple lesions occur in the same area or the lesions may spread to other areas of the body.
Pyogenic granulomas are raised, bright red lesions that may be small or large and smooth or bumpy. They grow quickly over weeks to months and may bleed a lot. These lesions are usually on the surface of the skin, but may form in the tissues below the skin and look like other vascular lesions.
Some pyogenic granulomas go away without treatment. Other pyogenic granulomas need treatment that may include the following:
Pyogenic granulomas often come back after treatment.
Angiofibromas appear as red bumps on the face.
Treatment of angiofibromas may include the following:
Juvenile Nasopharyngeal Angiofibroma
Juvenile nasopharyngeal angiofibromas are benign tumors but they can grow into nearby tissue. They begin in the nasal cavity and may spread to the nasopharynx, the paranasal sinuses, the bone around the eyes, and sometimes to the brain.
Treatment of juvenile nasopharyngeal angiofibromas may include the following:
Intermediate Tumors that Spread Locally
For information about the treatments listed below, see the Treatment Option Overview section.
Kaposiform Hemangioendothelioma and Tufted Angioma
Kaposiform hemangioendotheliomas and tufted angiomas are blood vessel tumors that occur in infants or young children. These tumors can cause Kasabach-Merritt phenomenon, a condition in which the blood is not able to clot and serious bleeding may occur. In Kasabach-Merritt phenomenon, the tumor traps and destroys platelets (blood-clotting cells). Then there aren't enough platelets in the blood when needed to stop bleeding. This type of vascular tumor is not related to Kaposi sarcoma.
Signs and Symptoms
Patients who have kaposiform hemangioendothelioma and tufted angioma may have anemia (weakness, feeling tired, or looking pale).
Treatment of kaposiform hemangioendotheliomas and tufted angiomas depends on the child's symptoms. Infection, delay in treatment, and surgery can cause bleeding that is life-threatening. Kaposiform hemangioendotheliomas and tufted angiomas are best treated by a vascular anomaly specialist.
Treatment and supportive care to manage bleeding may include the following:
- Steroid therapy which may be followed by chemotherapy.
- Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin.
- Immunotherapy (interferon).
- Antifibrinolytic therapy to improve blood clotting.
- Chemotherapy with one or more anticancer drugs.
- Beta-blocker therapy (propranolol).
- Surgery (excision) to remove the tumor, with or without embolization.
- Targeted therapy (sirolimus), with or without steroid therapy.
- A clinical trial of chemotherapy or targeted therapy (sirolimus).
Even with treatment, these tumors do not fully go away and can come back. Pain and inflammation may get worse with age, often around the time of puberty. Long-term effects include chronic pain, heart failure, bone problems, and lymphedema (the build up of lymph fluid in tissues).
Intermediate Tumors that Rarely Spread
For information about the treatments listed below, see the Treatment Option Overview section.
Pseudomyogenic hemangioendothelioma can occur in children, but is most common in men between 20 and 50 years of age. These tumors are rare, and usually occur on or under the skin, or in bone. They may spread to nearby tissue, but usually do not spread to other parts of the body. In most cases, there are multiple tumors.
Signs and Symptoms
Pseudomyogenic hemangioendotheliomas may appear as a lump in soft tissue or may cause pain in the affected area.
Treatment of pseudomyogenic hemangioendotheliomas may include the following:
Because pseudomyogenic hemangioendothelioma is so rare in children, treatment options are based on clinical trials in adults.
Retiform hemangioendotheliomas are slow growing, flat tumors that occur in young adults and sometimes children. These tumors usually occur on or under the skin of the arms, legs, and trunk. These tumors usually do not spread to other parts of the body.
Treatment of retiform hemangioendotheliomas may include the following:
Retiform hemangioendothelioma may come back after treatment.
Papillary Intralymphatic Angioendothelioma
Papillary intralymphatic angioendotheliomas may appear as firm, raised, purplish bumps, which may be small or large.
Treatment of papillary intralymphatic angioendotheliomas may include the following:
Composite hemangioendotheliomas have features of both benign and malignant vascular tumors. These tumors usually occur on or under the skin on the arms or legs. They may also occur on the head, neck, or chest. Composite hemangioendotheliomas are not likely to metastasize (spread) but they may come back in the same place. When the tumors metastasize, they usually spread to nearby lymph nodes.
Treatment of composite hemangioendotheliomas may include the following:
Kaposi sarcoma is a cancer that causes lesions to grow in the skin; the mucous membranes lining the mouth, nose, and throat; lymph nodes; or other organs. It is caused by the Kaposi sarcoma herpes virus (KSHV). In the United States, it occurs most often in children who have a weak immune system caused by rare immune system disorders, HIV infection, or drugs used in organ transplants.
Signs in children may include the following:
Treatment of Kaposi sarcoma may include the following:
Because Kaposi sarcoma is so rare in children, some treatment options are based on clinical trials in adults. See the PDQ summary on Kaposi Sarcoma Treatment for information about Kaposi sarcoma in adults.
For information about the treatments listed below, see the Treatment Option Overview section.
Epithelioid hemangioendotheliomas can occur in children, but are most common in adults between 30 and 50 years of age. They usually occur in the liver, lung, or in bone. They may be fast growing or slow growing. In about a third of cases, the tumor spreads to other parts of the body very quickly.
Signs and Symptoms
- On the skin, the tumors can be raised and rounded or flat, red-brown patches that feel warm.
- In the lung, there may be no early symptoms. Signs and symptoms that may occur include:
- In bone, the tumors can cause breaks.
Tumors that occur in the liver or soft tissue may also cause signs and symptoms.
Epithelioid hemangioendotheliomas in the liver are found with CT scans and MRI scans. See the General Information section for a description of these tests and procedures used to diagnose epithelioid hemangioendothelioma and find out whether the tumor has spread. X-rays may also be done.
Treatment of slow-growing epithelioid hemangioendotheliomas includes the following:
Treatment of fast-growing epithelioid hemangioendotheliomas may include the following:
- Surgery to remove the tumor when possible.
- Immunotherapy (interferon) and targeted therapy (thalidomide, sorafenib, pazopanib, sirolimus) for tumors that are likely to spread.
- Total hepatectomy and liver transplant when the tumor is in the liver.
- A clinical trial of targeted therapy (trametinib).
- A clinical trial of chemotherapy and targeted therapy (pazopanib).
Angiosarcoma of the Soft Tissue
Angiosarcomas are fast-growing tumors that form in blood vessels or lymph vessels in any part of the body, usually in soft tissue. Most angiosarcomas are in or near the skin. Those in deeper soft tissue can form in the liver, spleen, and lung.
These tumors are very rare in children. Children sometimes have more than one tumor in the skin and/or liver.
Anything that increases your risk of getting a disease is called a risk factor. Having a risk factor does not mean that you will get the disease; not having risk factors doesn’t mean that you will not get the disease. Talk with your child's doctor if you think your child may be at risk. Risk factors for angiosarcomas include the following:
Signs of angiosarcoma depend on where the tumor is and may include the following:
- Red patches on the skin that bleed easily.
- Purple tumors.
Treatment of angiosarcoma may include the following:
- Surgery to completely remove the tumor.
- A combination of surgery, chemotherapy, and radiation therapy for angiosarcomas that have spread.
- Targeted therapy (bevacizumab) and chemotherapy for angiosarcomas that began as infantile hemangiomas.
- A clinical trial of chemotherapy with or without targeted therapy (pazopanib).
- A clinical trial of immunotherapy (nivolumab and ipilimumab).
To Learn More About Childhood Vascular Tumors
For more information about childhood vascular tumors, see the following:
For more childhood cancer information and other general cancer resources, see the following:
- About Cancer
- Childhood Cancers
- CureSearch for Children's Cancer
- Late Effects of Treatment for Childhood Cancer
- Adolescents and Young Adults with Cancer
- Children with Cancer: A Guide for Parents
- Cancer in Children and Adolescents
- Coping with Cancer
- Questions to Ask Your Doctor about Cancer
- For Survivors and Caregivers
About This PDQ Summary
Physician Data Query (PDQ) is the National Cancer Institute's (NCI's) comprehensive cancer information database. The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries come in two versions. The health professional versions have detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions have cancer information that is accurate and up to date and most versions are also available in Spanish.
PDQ is a service of the NCI. The NCI is part of the National Institutes of Health (NIH). NIH is the federal government’s center of biomedical research. The PDQ summaries are based on an independent review of the medical literature. They are not policy statements of the NCI or the NIH.
Purpose of This Summary
This PDQ cancer information summary has current information about the treatment of childhood vascular tumors. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care.
Reviewers and Updates
Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts in cancer treatment and other specialties related to cancer. The summaries are reviewed regularly and changes are made when there is new information. The date on each summary ("Updated") is the date of the most recent change.
The information in this patient summary was taken from the health professional version, which is reviewed regularly and updated as needed, by the PDQ Pediatric Treatment Editorial Board.
Clinical Trial Information
A clinical trial is a study to answer a scientific question, such as whether one treatment is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. During treatment clinical trials, information is collected about the effects of a new treatment and how well it works. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Permission to Use This Summary
PDQ is a registered trademark. The content of PDQ documents can be used freely as text. It cannot be identified as an NCI PDQ cancer information summary unless the whole summary is shown and it is updated regularly. However, a user would be allowed to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks in the following way: [include excerpt from the summary].”
The best way to cite this PDQ summary is:
PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Vascular Tumors Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/patient/child-vascular-tumors-treatment-pdq. Accessed <MM/DD/YYYY>. [PMID: 27253005]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use in the PDQ summaries only. If you want to use an image from a PDQ summary and you are not using the whole summary, you must get permission from the owner. It cannot be given by the National Cancer Institute. Information about using the images in this summary, along with many other images related to cancer can be found in Visuals Online. Visuals Online is a collection of more than 3,000 scientific images.
The information in these summaries should not be used to make decisions about insurance reimbursement. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s E-mail Us.